Etretinate

Etretinate
Clinical data
Trade names	Tigason, formerly Tegison
AHFS/Drugs.com	Drugs.com archive
MedlinePlus	a601010
Routes of; administration	Oral
ATC code	D05BB01 (WHO) ;
Legal status
Legal status	BR: Class F4 (Other prohibited substances); US: Withdrawn;
Pharmacokinetic data
Protein binding	>99%
Metabolites	Free acid, Z-form, chain shortening
Elimination half-life	120 days
Identifiers
	IUPAC name Ethyl (2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoate;
CAS Number	54350-48-0 ;
PubChem CID	5282375;
IUPHAR/BPS	7599;
DrugBank	DB00926 ;
ChemSpider	4445538 ;
UNII	65M2UDR9AG;
KEGG	D00316 ;
ChEBI	CHEBI:4913 ;
ChEMBL	ChEMBL464 ;
CompTox Dashboard (EPA)	DTXSID0023036 ;
ECHA InfoCard	100.053.727
Chemical and physical data
Formula	C23H30O3
Molar mass	354.490 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC)\C=C(\C=C\C=C(\C=C\c1c(cc(OC)c(c1C)C)C)C)C;
	InChI InChI=1S/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+ ; Key:HQMNCQVAMBCHCO-DJRRULDNSA-N ;
	(what is this?) (verify)

Etretinate (trade name Tegison) is a medication developed by Hoffmann–La Roche that was approved by the FDA in 1986 to treat severe psoriasis. It is a second-generation retinoid. It was subsequently removed from the Canadian market in 1996 and the United States market in 1998 due to the high risk of birth defects. It remains on the market in Japan as Tigason.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.